FIELD: pharmaceutics.
SUBSTANCE: invention relates to solid pharmaceutical compositions of daptomycin for treating bacterial infections. Above composition is obtained by freeze-drying or spray drying of aqueous solution of daptomycin or buffer composition of daptomycin containing daptomycin and at least one excipient selected from sucrose or trehalose, wherein molar ratio of daptomycin to excipient ranges from 1:1.12 to 1:21.32. Invention also relates to production and use of said compositions.
EFFECT: invention provides faster restoration of lyophilized composition of daptomycin in aqueous pharmaceutical diluent, as well as high chemical stability of daptomycin both in form of solid substance and in reduced liquid phases.
25 cl, 8 dwg, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| NEW ALBUMIN-FREE COMPOSITIONS OF FACTOR VIII | 2000 |
|
RU2244556C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PLASMINOGEN, AND USE THEREOF | 2015 |
|
RU2711989C2 |
| NOVEL STABILISER FOR PHARMACEUTICAL PROTEINS | 2011 |
|
RU2571496C2 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| NOVEL STABILIZER FOR PHARMACEUTICAL PROTEINS | 2011 |
|
RU2707090C2 |
| RESISTANT LOOFING-PROOF TRIPEPTIDES | 2014 |
|
RU2684915C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| FORMULATIONS WITH ADENO-ASSOCIATED VIRUS | 2017 |
|
RU2769196C2 |
| PHARMACEUTICAL COMPOSITION OF FUSION PROTEIN TACI-FC | 2020 |
|
RU2779387C1 |
